

## **WHO Expert Consultation meeting on Antimicrobial Resistance (AMR) Health Burden Estimation**

**18-19 January 2018  
Geneva, Switzerland, WHO HQ**

**Room M605  
Agenda**

### **THURSDAY, 18 JANUARY 2018**

8:30-8:45	<b>Welcome and introductions (C Pessoa)</b>  <b>Meeting format, objectives and desired outcomes</b> <ul style="list-style-type: none"> <li>Meeting objectives, rules and procedures</li> <li>Election of chairs</li> </ul>
<b>SESSION 1: Current and past history of burden calculation for health conditions</b>	
8:45-9:00	<b>GLASS – Global AMR Surveillance System (C Pessoa) (10' + 5')</b>
9:00- 9:25	<b>Review on study designs and methodological challenges to monitor clinical burden of multiresistant bacteria – Limitations &amp; potential avenues (E Tacconelli) (20' + 5')</b>
9:25-9:50	<b>Estimation of MDR-TB prevalence &amp; derivation of metrics for MDR-TB burden calculation (P Glaziou) (20' + 5')</b>
9:50-10:05	<i>Coffee break</i>
<b>SESSION 2: Approaches and methods to estimate AMR health burden</b>	
10:05-10:20	<b>PANORAMA project -- short overview (A Stewardson) (10' + 5')</b>
10:20-10:35	<b>From AMR Surveillance to AMR Burden (V Thamlikitkul) (10' + 5')</b>
10:35-12:00	<b>Context &amp; targets (open discussion)</b> <ul style="list-style-type: none"> <li>Objectives of health burden estimation</li> <li>Criteria to apply when generating data (e.g., representativeness, feasibility, cost)</li> <li>Target population</li> <li>Health conditions of interest (type of infection)</li> <li>Compile case-definitions and health states</li> <li>Exposure: susceptible and non-susceptible pathogen/s of interest</li> </ul>
12:00-13:30	<i>Lunch together (Crystal Restaurant, WHO/HQ, Main Building)</i>

<b>SESSION 2 (Cont.): Approaches and methods to AMR health burden estimation</b>	
13:30-13:40	<b>Simulation models for burden estimation (N Hens) (10' + 5')</b>
13:40-15:30	<b>What we need – outline steps for definition of: (open discussion)</b> <ul style="list-style-type: none"> <li>• methods for burden evaluation (e.g. outcome trees)</li> <li>• metrics to be measured (e.g., prevalence, incidence, mortality)</li> <li>• covariates to be collected</li> <li>• confounders to be considered (e.g. adequacy of antibiotic therapy, severity of illness)</li> <li>• metrics to be generated and adjustments approaches (e.g., DW, DALYs)</li> </ul>
15:30-15:50	<i>Coffee break</i>
15:50-16:05	<b>Burden estimates from DRIVE-AB and using the HECTOR methodology to supplement them (Y Carmeli) (10' + 5')</b>
16:05-17:30	<b>Explore potential approaches for pilot studies and identify strengths and limitations (open discussion)</b>

---

## FRIDAY, 19 JANUARY 2018

<b>SESSION 3: Development of protocols &amp; pilot studies for AMR burden estimation</b>	
8:30-8:45	<b>Potential synergies with other GBD projects (A Stergachis) (10' + 5')</b>
8:45-10:30	<b>How to do it (open discussion)</b> <ul style="list-style-type: none"> <li>• Potential study designs and associated challenges</li> <li>• Sampling strategy and data collection protocols (LMICs, HICs)</li> </ul>
10:30-10:45	<i>Coffee break</i>
10:45-12:00	<b>How to do it (open discussion continued)</b>
12:30-13:00	<b>Planned activities and steps forward (open discussion)</b>
13:00	<b>Meeting closure</b>